Intensive cholesterol control in high risk patients can reduce cardiovascular events by 20%

Reducing cholesterol to very low levels by treating high risk patients with a statin as well as a proprotein convertase subtilisin-kexin type 9 (PSCK9) inhibitor is associated with a 20% reduction in cardiovascular events, a secondary analysis of a randomised study has reported.1

“Our findings demonstrate that there is essentially no floor effect, and that lower levels translated to a greater reduction in risk,” said lead author Robert Giugliano, from the Brigham and Women’s Hospital in Boston, US. He added, “Among …